Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer.

Naoya NishiokaTateaki NaitoAkifumi NotsuKeita MoriHiroaki KodamaEriko MiyawakiTaichi MiyawakiNobuaki MamesayaHaruki Kobayashi Shota Omori Kazushige Wakuda Akira Ono Hirotsugu Kenmotsu Haruyasu MurakamiKoichi TakayamaToshiaki Takahashi

Published in: Cancer medicine (2020)

Lumbar skeletal muscle quality has the potential to predict the therapeutic effect of anti-programed cell death 1/programed cell death ligand 1 inhibitor monotherapy in patients with advanced NSCLC.

Keyphrases

advanced non small cell lung cancer
cell death
skeletal muscle
epidermal growth factor receptor
cell cycle arrest
small cell lung cancer
insulin resistance
minimally invasive
combination therapy
type diabetes
open label
randomized controlled trial
metabolic syndrome
human health
climate change
pi k akt